A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction

Study Purpose

The aim of this study is to assess whether increasing oral doses of Riociguat are safe and improve the well-being, symptoms and outcome in patients with pulmonary hypertension associated with left ventricular systolic dysfunction

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years - 80 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Male and female patients with symptomatic pulmonary hypertension due to left ventricular systolic dysfunction despite optimized heart failure therapy.

Exclusion Criteria:

- Types of pulmonary hypertension other than group 2.1 of Dana Point Classification

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT01065454
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Bayer
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Bayer Study Director
Principal Investigator Affiliation Bayer
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Active, not recruiting
Countries Australia, Austria, Belgium, Canada, China, Czechia, Denmark, France, Germany, Italy, Japan, Netherlands, Poland, Singapore, Spain, Switzerland, United Kingdom, United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Hypertension, Pulmonary, Ventricular Dysfunction, Left
Additional Details

Pharmacokinetics parameters were regarded as exploratory parameters. Adverse event data will be covered in Adverse events section.

Arms & Interventions

Arms

Experimental: Riociguat (Adempas, BAY63-2521) up to 2 mg

Participants received riociguat up to 2 mg three times per day (tid) (increasing from 0.5 to 1 to 2 mg).

Experimental: Riociguat (Adempas, BAY63-2521) up to 1 mg

Participants received riociguat up to 1 mg tid (increasing from 0.5 to 1 mg).

Experimental: Riociguat (Adempas, BAY63-2521) fixed 0.5 mg

Participants received riociguat 0.5 mg tid (fixed dose).

Placebo Comparator: Placebo

Participants received placebo tid.

Interventions

Drug: - Riociguat (Adempas, BAY63-2521)

up to 2 mg three times a day (increasing from 0.5 to 1 to 2 mg)

Drug: - Riociguat (Adempas, BAY63-2521)

up to 1 mg three times a day (increasing from 0.5 to 1 mg)

Drug: - Riociguat (Adempas, BAY63-2521)

fixed 0.5 mg three times a day

Drug: - Placebo

Placebo three times a day

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Fountain Valley, California

Status

Address

Fountain Valley, California, 92708

Los Angeles, California

Status

Address

Los Angeles, California, 90073

San Diego, California

Status

Address

San Diego, California, 92103

Torrance, California

Status

Address

Torrance, California, 90502

Miami, Florida

Status

Address

Miami, Florida, 33136

Iowa City, Iowa

Status

Address

Iowa City, Iowa, 52242

Baltimore, Maryland

Status

Address

Baltimore, Maryland, 21201

Boston, Massachusetts

Status

Address

Boston, Massachusetts, 02114

Rochester, Minnesota

Status

Address

Rochester, Minnesota, 55905

Saint Louis, Missouri

Status

Address

Saint Louis, Missouri, 63110

Cincinnati, Ohio

Status

Address

Cincinnati, Ohio, 45219

Fairfield, Ohio

Status

Address

Fairfield, Ohio, 45014

Falls Church, Virginia

Status

Address

Falls Church, Virginia, 22042

Milwaukee, Wisconsin

Status

Address

Milwaukee, Wisconsin, 53215

International Sites

Darlinghurst, New South Wales, Australia

Status

Address

Darlinghurst, New South Wales, 2010

Chermside, Queensland, Australia

Status

Address

Chermside, Queensland, 4032

Prahran, Victoria, Australia

Status

Address

Prahran, Victoria, 3181

Innsbruck, Tirol, Austria

Status

Address

Innsbruck, Tirol, 6020

Wien, Austria

Status

Address

Wien, , 1090

Aalst, Belgium

Status

Address

Aalst, , 9300

Bruxelles - Brussel, Belgium

Status

Address

Bruxelles - Brussel, , 1070

Gent, Belgium

Status

Address

Gent, , 9000

Leuven, Belgium

Status

Address

Leuven, , 3000

Edmonton, Alberta, Canada

Status

Address

Edmonton, Alberta, T6G 2B7

Vancouver, British Columbia, Canada

Status

Address

Vancouver, British Columbia, V5Z 1M9

Montreal, Quebec, Canada

Status

Address

Montreal, Quebec, H3T 1E2

Quebec, Canada

Status

Address

Quebec, , G1V 4G5

Beijing, China

Status

Address

Beijing, , 100020

Shanghai, China

Status

Address

Shanghai, , 200433

Shanghai, China

Status

Address

Shanghai, ,

Brno, Czechia

Status

Address

Brno, , 656 91

Olomouc, Czechia

Status

Address

Olomouc, , 779 00

Praha 2, Czechia

Status

Address

Praha 2, , 12808

Praha 4, Czechia

Status

Address

Praha 4, , 140 21

Aarhus N, Denmark

Status

Address

Aarhus N, , 8200

Bron, France

Status

Address

Bron, , 69500

Lille Cedex, France

Status

Address

Lille Cedex, , 59037

Nantes, France

Status

Address

Nantes, , 44035

Pessac, France

Status

Address

Pessac, , 33604

Rouen, France

Status

Address

Rouen, , 76031

Toulouse, France

Status

Address

Toulouse, , 31403

Heidelberg, Baden-Württemberg, Germany

Status

Address

Heidelberg, Baden-Württemberg, 69120

Augsburg, Bayern, Germany

Status

Address

Augsburg, Bayern, 86156

Greifswald, Mecklenburg-Vorpommern, Germany

Status

Address

Greifswald, Mecklenburg-Vorpommern, 17475

Köln, Nordrhein-Westfalen, Germany

Status

Address

Köln, Nordrhein-Westfalen, 50924

Erfurt, Thüringen, Germany

Status

Address

Erfurt, Thüringen, 99089

Napoli, Campania, Italy

Status

Address

Napoli, Campania, 80131

Pavia, Lombardia, Italy

Status

Address

Pavia, Lombardia, 27100

Nagoya, Aichi, Japan

Status

Address

Nagoya, Aichi, 466-8560

Seto, Aichi, Japan

Status

Address

Seto, Aichi, 489-8642

Ogaki, Gifu, Japan

Status

Address

Ogaki, Gifu, 503-8502

Higashiibaraki, Ibaraki, Japan

Status

Address

Higashiibaraki, Ibaraki, 311-3193

Tsu, Mie, Japan

Status

Address

Tsu, Mie, 514-1101

Sendai, Miyagi, Japan

Status

Address

Sendai, Miyagi, 980-8574

Suita, Osaka, Japan

Status

Address

Suita, Osaka, 565-0871

Kusatsu, Shiga, Japan

Status

Address

Kusatsu, Shiga, 525-8585

Sunto, Shizuoka, Japan

Status

Address

Sunto, Shizuoka, 411-8611

Arakawa-ku, Tokyo, Japan

Status

Address

Arakawa-ku, Tokyo, 116-8567

Shinjuku-ku, Tokyo, Japan

Status

Address

Shinjuku-ku, Tokyo, 162-8666

Tanabe, Wakayama, Japan

Status

Address

Tanabe, Wakayama, 646-8558

Osaka, Japan

Status

Address

Osaka, , 530-8480

Osaka, Japan

Status

Address

Osaka, , 541-8567

Amsterdam, Netherlands

Status

Address

Amsterdam, , 1081 HV

Amsterdam, Netherlands

Status

Address

Amsterdam, , 1091 AC

Nijmegen, Netherlands

Status

Address

Nijmegen, , 6500HB

Bydgoszcz, Poland

Status

Address

Bydgoszcz, , 85-168

Gdansk, Poland

Status

Address

Gdansk, , 80-214

Warszawa, Poland

Status

Address

Warszawa, , 04-628

Singapore, Singapore

Status

Address

Singapore, , 119228

Singapore, Singapore

Status

Address

Singapore, , 168752

Singapore, Singapore

Status

Address

Singapore, , 308433

Majadahonda, Madrid, Spain

Status

Address

Majadahonda, Madrid, 28222

El Palmar, Murcia, Spain

Status

Address

El Palmar, Murcia, 30120

Palma, Palma De Mallorca, Spain

Status

Address

Palma, Palma De Mallorca, 07198

A Coruña, Spain

Status

Address

A Coruña, , 15006

Barcelona, Spain

Status

Address

Barcelona, , 08003

Madrid, Spain

Status

Address

Madrid, , 28041

Valencia, Spain

Status

Address

Valencia, , 46026

Geneva, Genève, Switzerland

Status

Address

Geneva, Genève, 1205

Lugano, Ticino, Switzerland

Status

Address

Lugano, Ticino, 6900

Zürich, Switzerland

Status

Address

Zürich, , 8091

Cambridge, United Kingdom

Status

Address

Cambridge, , CB23 3RE

London, United Kingdom

Status

Address

London, , SW3 6NP

For more information, please contact PHA at Research@PHAssociation.org and refer to the terms of service below.

Submit Feedback

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation in a clinical trial or study.